Zadaxin thymosin alpha 1 plus interferon: Phase II results; Phase III

Twelve-month follow-up data from a Turkish Phase II trial in 31 patients with chronic HBV showed that 71% (15/21) of patients treated with Zadaxin plus alpha interferon from Schering-Plough Corp. (SG...